Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CNR1 | P21554 | 1/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.74 |
| ▸ | HRH1 | P35367 | 1/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774484 | 0.87 | SLC6A2 (0.75) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL14046643 | 0.87 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL23079054 | 0.86 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL4309058 | 0.85 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL1070272 | 0.85 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL1560692 | 0.85 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| (S)-Venlafaxine SCHEMBL3644633 | 0.85 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL10616028 | 0.85 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL10614031 | 0.85 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL27838459 | 0.85 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933123-B2 | Polymorphic forms of O-desmethyl-venlafaxine succinate | CADILA HEALTHCARE LIMITED (IN) | 2015-01-13 | — | — | US | disclosed |
| US-8933123-B2 | Polymorphic forms of O-desmethyl-venlafaxine succinate | CADILA HEALTHCARE LIMITED (IN) | 2015-01-13 | — | — | US | disclosed |
| US-20120264828-A1 | POLYMORPHIC FORMS OF O-DESMETHYL-VENLAFAXINE SUCCINATE | CADILA HEALTHCARE LIMITED | 2012-10-18 | — | — | US | disclosed |
| US-20120264828-A1 | POLYMORPHIC FORMS OF O-DESMETHYL-VENLAFAXINE SUCCINATE | CADILA HEALTHCARE LIMITED | 2012-10-18 | — | — | US | disclosed |
| WO-2012046250-A2 | POLYMORPHIC FORMS OF O-DESMETHYL-VENLAFAXINE SUCCINATE FIELD OF THE INVENTION | CADILA HEALTHCARE LIMITED (IN) | 2012-04-12 | — | — | WO | disclosed |
| US-20100121108-A1 | PROCESS FOR SYNTHESIZING DESVENLAFAXINE FREE BASE AND SALTS OR SOLVATES THEREOF | MEDICHEM, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100121108-A1 | PROCESS FOR SYNTHESIZING DESVENLAFAXINE FREE BASE AND SALTS OR SOLVATES THEREOF | MEDICHEM, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| WO-2008015584-A2 | IMPROVED PROCESS FOR SYNTHESIZING DESVENLAFAXINE FREE BASE AND SALTS OR SOLVATES THEREOF | MEDICHEM, S.A. (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264828-A1 | POLYMORPHIC FORMS OF O-DESMETHYL-VENLAFAXINE SUCCINATE | COMT, CYP2D6, SLC6A4 | SLC6A2 4/4885SLC6A4 3/4885SLC6A3 6/4885 |
| US-20100121108-A1 | PROCESS FOR SYNTHESIZING DESVENLAFAXINE FREE BASE AND SALTS OR SOLVATES THEREOF | SLC6A4, VGF, SLC6A2 | SLC6A2 3/4885SLC6A4 1/4885SLC6A3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.